End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.7 SEK | +1.09% | -.--% | +4.14% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- With an expected P/E ratio at 50.52 and 29.24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.14% | 106M | D | ||
+3.41% | 32.18B | C | ||
+14.79% | 7.33B | C- | ||
+20.38% | 3.83B | B- | ||
-14.26% | 3.23B | C- | ||
-27.90% | 1.25B | B | ||
-34.43% | 1.12B | - | ||
+2.01% | 912M | C | ||
-24.21% | 856M | - | C+ | |
-38.47% | 859M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- SYNT Stock
- Ratings SyntheticMR AB